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A B S T R A C T
Cystic ﬁbrosis (CF), one of the most common lethal hereditary diseases of white European populations, is
caused by loss-of-function mutations in the CF Transmembrane conductance Regulator (CFTR) gene. One
of the main causes of mortality is the onset of CF lung disease, which is characterized by chronic infection
and inﬂammation resulting in the progressive remodelling, irreversible damage and ﬁbrosis of the
airways. An increasing number of studies indicate that sphingolipids are crucial players in pulmonary
manifestations of CF, even if their direct involvement in CF lung disease is still unclear. In this review, we
give an overview of the role of sphingolipids in CF pulmonary disease, focusing on the relationship
between glycosphingolipids and lung inﬂammation, which represents the main hallmark of this disease.
ã 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cystic ﬁbrosis (CF) is one of the most common lethal hereditary
and monogenic disorders among people of white European
descent, although it has been reported in all races. It is an
inherited autosomal recessive disease caused by mutations in a
single gene, consisting of 27 exons, which codes for the Cystic
Fibrosis Transmembrane conductance Regulator (CFTR) protein
(Riordan et al., 1989). It is a large multidomain protein comprising* Corresponding authors.
E-mail addresses: massimo.aureli@unimi.it (M. Aureli),
cristina.dechecchi@ospedaleuniverona.it (M.C. Dechecchi).
1 These authors equally contributed to this work.
http://dx.doi.org/10.1016/j.chemphyslip.2016.08.002
0009-3084/ã 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acce
nc-nd/4.0/).1480 amino acid residues arranged in two membrane-spanning
domains (MSD 1, 2), two nucleotide (ATP) binding domains (NBD1,
2), and a unique regulatory domain (RD) with multiple phosphor-
ylation sites (Riordan, 2008; Billet et al., 2015). The CFTR protein is
a cAMP-activated chloride channel expressed at the apical
membrane of most of the surface epithelial cells lining the airways
and the gastrointestinal tract, exocrine pancreas, airway submu-
cosal and sweat glands. It plays a key role in hydrating airway
secretions and regulating other cellular functions, including Na+
transport in airway epithelia (Welsh and Smith, 2001; Cutting,
2010). There are more than 2000 sequence variations in the CFTR
gene, many of which have been associated with causing diseases
(see the Cystic Fibrosis Mutation Database of the Cystic Fibrosis
Gene Analysis Consortium, www.genet.sickkids.on.ca/cftr/). Thess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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the loss of phenylalanine at position 508 of the protein from the
ﬁrst NBD1, causes a folding defect in the protein and impaired
localization of the CFTR channel on the apical surface of epithelial
cells, leading to defective epithelial ion transport (Cheng et al.,
1990; Du et al., 2005). This mutation occurs in approximately 70%
of CF chromosomes worldwide, in at least one allele of 90% of CF
patients, and it is associated with a severe clinical phenotype. The
consequences of mutated CFTR are considerable in the respiratory
tract (Wright et al., 2006). Here, mutations in CFTR impair the
mucociliary clearance due to reduced periciliary ﬂuid volume and
increased viscosity of submucosal gland secretions, leading to
chronic bacterial infections mostly caused by Pseudomonas
aeruginosa (P.aeruginosa) (Mogayzel and Flume, 2010). The
destruction of the airways in chronically colonized CF individuals
is due to a massive inﬂux of polymorphonuclear neutrophils (PMN)
in the bronchial lumen. This is orchestrated by the bronchial
epithelial cells secreting the neutrophilic chemokine interleukin 8
(IL-8) in response to continuous stimulation by bacteria or their
products (Bezzerri et al., 2011; Cohen and Prince, 2012) which
activate a series of kinases and transcription factors depending on
Toll-like Receptor signalling (Bezzerri et al., 2011). Obstructive lung
disease is currently the primary cause of morbidity and is
responsible for about 80% of mortality (Cutting, 2015).
2. Overview of sphingolipid homeostasis
Sphingolipids (SLs) are minor cell components of all mammal
cell membranes with the hydrophilic head group protruding
toward the extracellular environment and the lipid moiety, the
Ceramide (Cer), deeply inserted into the membrane bilayer (Feizi,
1985). In the plasma membrane (PM), they reside asymmetrically
in the extracellular leaﬂet, where they are concentrated in
restricted membrane areas known as “lipid rafts” or “sphingolipid
and cholesterol enriched membrane domains” (Sonnino et al.,Fig. 1. Schematic representation of the major routes and the subcellular sites of sphin
The pathways of sphingolipid metabolism include their catabolism in the endolysosoma
apparatus (2). A ﬁne-tuning of SL composition can also occur at the cell surface through 
(light blue circle); galactose (yellow circle); N-acetyl-galactosamine (yellow square); si2006). It is believed that in lipid rafts, SLs modulate the functional
features of several membrane proteins (Prinetti et al., 2009) by
both direct lateral interactions between SLs and plasma membrane
proteins (Kabayama et al., 2007), and by short-range alterations of
the physico-chemical properties of the protein membrane
microenvironment (Sonnino et al., 2009).
SLs are important in the regulation of cell functions, and cells
employ different strategies to establish the proper pattern of SLs at
the plasma membrane. SLs are synthesized through complex
metabolic networks involving neo-biosynthesis, catabolism and
complex intracellular trafﬁcking, as well as exchanges with the
extracellular environment. A general schematic of SL metabolism,
as a well as of their intracellular transport, is depicted in Fig. 1.
Cer plays a key role in SL metabolism, since it is the common
intermediary in both SL biosynthetic (sphingomyelin and glyco-
sphingolipids biosynthesis) and catabolic pathways.
The de novo biosynthesis of Cer occurs at the cytosolic face of
the endoplasmic reticulum and starts with the condensation of L-
serine to a fatty acyl-coenzyme A, usually palmitoyl-CoA. This
reaction is catalysed by vitamin B6-dependent serine palmitoyl-
transferase and produces 3-ketosphinganine (Mandon et al., 1991;
Nagiec et al., 1994; Weiss and Stoffel, 1997), which is then reduced
to D-erythro-sphinganine by 3-ketosphinganine reductase, a
NADPH-dependent reaction (Stoffel et al., 1970). Sphinganine is
subsequently acylated to dihydroCer by a family of six Cer
synthases, integral membrane proteins, each of which displays a
different speciﬁcity to Acyl-CoAs (Merrill and Wang, 1986; Rother
et al., 1992; Shimeno et al., 1998). Most of the dihydroCer pool is
then desaturated to Cer via the dihydroCer desaturase reaction
(Geeraert and van Veldhoven, 1997; Michel et al., 1997; Mikami
et al., 1998). Once synthesized, Cer is directly routed to the
membrane or used as a precursor for glycosphingolipids (GSL) or
sphingomyelin (SM) biosynthesis. In particular, SM can be formed
at the Golgi apparatus or at the plasma membrane by SM synthase
1 and SM synthase 2, respectively. Both isoforms transfergolipid metabolism.
l compartments (1) and their biosynthesis in the endoplasmic reticulum and Golgi
the action of plasma membrane glycosyltransferases and glycosidases (3). -Glucose
alic acid (purple diamond); methyl-choline (red rectangle).
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diacylglycerol as a by-product of the reaction.
Conversely, GSL biosynthesis begins with glycosylation of Cer to
glucosylCer (GlcCer) via the action of GlcCer synthase at the
cytosolic side of early Golgi membranes (Jeckel et al., 1992). Once
formed, GlcCer can be translocated to the luminal side of the Golgi
where it is further metabolized by different membrane-bound
glycosyltransferases, which catalyse the sequential addition of
sugar residues, leading to the generation of GSL oligosaccharideFig. 2. Sphingolipid neo-biosynthetic pathway.
The de novo byosinthesis of ceramide (Cer) occurs at the endoplasmic reticulum by the 
reductase: 3-ketosphinganine reductase; CerS: ceramide synthase; dhCer desaturase: d
Ceramide can then reach directly the inner leaﬂet of the PM, where it is converted by the s
where it is converted to glycosphingolipids (GSL) or to SM by SM synthase-1 (SMS1). Th
transferase (GlcT1) with the formation of glucosylceramide (GlcCer). GlcCer is transferre
the hydrophilic head (GalT1: galactosyl transferase 1; SAT1: GM3 synthase; GalNacT: 
transport.chains (Fig. 2). GlcCer can also be directly transferred to the plasma
membrane (Warnock et al., 1994).
SLs degradation take place in the acidic compartments of cells,
the lysosomes, where PM SLs are transported by endocytic
vesicular ﬂow through early and late endosomal compartments.
In lysosomes, GSLs are catabolized by different exoglycosidases
that sequentially cleave off the sugar residues from the non-
reducing end of their SL substrates. In the same compartment, SM
is directly catabolized to Cer by the acid sphingomyelinase. Cersequential action of different enzymes (SPT: serine palmitoyl-transferase; 3KdhSph
ihydro ceramide desaturase).
phingomyelin synthase 2 (SMS2) to SM. Conversely, Cer reaches the Golgi apparatus
e GSL synthesis starts at the cytosolic side of the Golgi apparatus by the action of a
d inside the Golgi apparatus where different transferases catalyse the maturation of
GM2 synthase; GalTII: GM1 synthase). GSL can then reach the PM by a vesicular
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to sphingosine and fatty acid by acid ceramidase. The resulting
catabolites, including the sphingoid bases, leave the lysosomes and
are either recycled or further degraded. During the catabolism of
sphingosine, sphingosine kinases ﬁrst phosphorylate it to sphin-
gosine 1 phosphate (S1P) and then sphingosine-1-phosphate lyase
degrades it to phosphoethanolamine and hexadecanal. It is widely
documented that S1P is not only a catabolic intermediate, but alsoFig. 3. Sphingolipid catabolism in the endo-lysosomal compartment.
Sphingolipids catabolism starts from invaginations of plasma membrane (PM) portion le
lysosome.
In secondary lysosome, different exoglycosidases sequentially cleave off the sugar residue
Cer can be also obtained from the sphingomyelin (SM) catabolism by the action of the
Acid-ceramidase (a-CERase) catalyse Cer in sphingosine (Sph) and fatty acid (FA).
In cytosol, sphingosine kinase (SK) phosphorylates Sph in sphingosine-1-phosphate (S1
lyase (S1P lyase).a secondary messenger playing a key role in the regulation of
several signalling pathways (Hannun and Obeid, 2008) (Fig. 3).
In addition to these main SL metabolism pathways, it is
nowadays accepted that SL synthesis and catabolism are triggered
directly at the cell surface by plasma membrane-associated
hydrolases and transferases (Fig. 4). Several enzymes for SL
metabolism have been found at the plasma membrane level,
including sialidase and sialyltransferase, sphingomyelinase andading to the formation of endocytic vesicles, which are incorporated in the primary
s from the non-reducing end of glycosphingolipids (GSL) producing ceramide (Cer).
 acidic-sphingomyelinase (a-SMase).
P), which is degraded to phosphoethanolamine and hexedecenal by the action of a
Fig. 4. Schematic representation of sphingolipid metabolism occurring at the cell surface.
The presence of both catabolic and anabolic enzymes of SL metabolism at the cell surface allows the in situ modulation of their composition at the plasma membrane level.
Among glycosyltransferases, GD3 synthase (SAT2), GM2-GD2 synthase (GalNac-T) and sphingomyelin synthase 2 (SMS2) have been also described at the cell surface. Among
the hydrolases found associated with plasma membrane, b-galactosidase (b-gal), b-galactocerebrosidase (b-gal), b-hexosaminidase A (HexA), b-glucocerebrosidase (GBA1)
and acid-sphingomyelinase (SMase) are the same enzymes present in the lysosomes, whereas sialidase NEU3 and non-lysosomal b-glucosylceramidase GBA2 are mainly
associated with the cell surface.
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b-glucosidases, ceramidase and two glycosyltransferases: GalNAc
transferase and sialyltranferase 2.
Several lines of evidence indicate that most of the PM-
associated hydrolases, such as b-galactosidase, b-galactocerebro-
sidase, b-hexosaminidase A, b-glucocerebrosidase GBA1, Neu1
and sphingomyelinase, are the same enzymes present in lyso-
somes. In contrast, sialidase NEU3 and non-lysosomal beta-
glucosylceramidase (GBA2) are located almost exclusively at the
plasma membrane. At this site, these enzymes may modulate the
metabolism of SLs directly at the cell surface, thus possibly
contributing in mediating the cellular effects exerted by SLs, as
well as to the regulation of the level of bioactive sphingoid
molecules, such as Cer and S1P.
3. Lung sphingolipids
The lung is characterized by the presence of a complex pattern
of SLs including Cer, phospho-SLs, neutral GSLs and gangliosides
(Hanqing et al., 1986). The adult human lung contains 85 nmol of
gangliosides and 140 nmol of neutral GSLs per gram wet weight.
Globosides, including globotetraosylCer and globotriaosylCer, are
the major classes of neutral glycolipids, followed by lactosylCer
(LacCer), glucosylCer (GlcCer) and tetahexosylCer (asialoGM1, A-
GM1). Fourteen gangliosides with different carbohydrate moieties
have been identiﬁed in sialylated GSLs in the adult human lung.
Among these, the most abundant are monosialogangliosides GM3
and GM1, disialo GD3, and trisialosyllactosylCer GT3 (Mansson
et al.,1986). The role of SLs and SL metabolism in lung development
has been widely investigated. In particular, the preservation of SL
rheostat synthesized by Cer, known to induce apoptosis, and S1P,
which promotes cell survival, is fundamental for the formation of
lung structure at all stages of lung development, as well as the
preservation of pulmonary physiology (Lee et al., 2015). Further-
more, de novo synthesis of Cer has been linked to apoptotic
endothelial cell death and a decreased pulmonary barrier function
(Petrache et al., 2005; Medler et al., 2008). Moreover, an excess of
Cer induces oxidative stress and apoptotic cell death leading to
alveolar enlargement (Petrache et al., 2008). Overall, these data
suggest that Cer regulation is necessary in maintaining lung
homeostasis. Different ﬁndings have demonstrated the involve-
ment of Cer in pulmonary infections caused by a variety of bacterial
and viral pathogens, including Neisseria gonorrhoeae, Neisseria
meningitidis, Staphylococcus aureus, Pseudomonas aeruginosa,
Listeria monocytogenes, Salmonella typhimurium, Escherichia coli,
mycobacteria, measles virus, rhinovirus, and sindbis virus (Seitz
et al., 2015). The important role of Cer in infections is due to its
biophysical properties. Cer molecules, displaying high hydropho-
bicity and low amphiphilicity, bind strongly to each other by meansof hydrophobic interactions, resulting in the formation of small
Cer-enriched membrane domains, which form platforms that are
larger than other parts of the cell membrane and characterized by
different biophysical membrane properties (Grassmé et al., 2001).
These Cer-enriched platforms trap and activate receptors and
signalling molecules, thus amplifying initial signals (Grassme et al.,
2003a,b). It has been shown that Cer-enriched platforms are
formed in cells after the application of many different stimuli,
including bacterial infections (Seitz et al., 2015). However, several
questions remain to be addressed; in particular, it is not clear if SL
misregulation is the cause or the consequence of these disorders.
4. Sphingolipid involvement in cystic ﬁbrosis lung infections
The airways of CF patients are characterized by large amounts of
pro-inﬂammatory mediators, such as interleukin-(IL)-8, IL-6 and
tumor necrosis factor-(TNF)-a, which continuously recruit neu-
trophils unable to kill bacteria, resulting in a vicious circle that
ampliﬁes inﬂammation and perpetuates infection (Mogayzel and
Flume, 2010). Binding of bacterial components to pattern-
recognition receptors expressed on epithelial cell surface, such
as Toll-like receptors (TLRs) 2, 4, and 5, activates a series of kinases
and adaptors, ultimately triggering nuclear translocation of
transcription factors and expression of pro-inﬂammatory genes
(Kawai and Akira, 2010; Bezzerri et al., 2011).
An increasing number of studies indicate that SLs play an
important regulatory role in CF with respect to pulmonary
infections and inﬂammation (Lahiri and Futerman, 2007; Guilbault
et al., 2008; Teichgraber et al., 2008; Uhlig and Gulbins, 2008;
Guilbault et al., 2009; Yu et al., 2009; Brodlie et al., 2010; Bodas
et al., 2011; Yang and Uhlig, 2011; Nahrlich et al., 2013).
In particular, some evidence suggests that GSLs associated with
the cell surface of epithelial cells can serve as receptors for
bacterial adhesion. In the case of P. aeruginosa, it has been shown,
by TLC binding assay using standard lipids, that several clinically
isolated strains of P. aeruginosa bind to A-GM1 and asialo-GM2 (A-
GM2). It is quite clear that they could be considered as receptors for
the P. aeruginosa; however, more confusing are the data reporting
the presence of these GSLs in the epithelial cells of lung and
bronchi. To our knowledge, no data are available regarding A-GM2,
whereas the presence of A-GM1 has been detected by the use of
antibodies on bronchial epithelial cells in culture (Krivan et al.,
1988a,b; Baker et al., 1990; de Bentzmann et al., 1996). Using ﬂow
cytometry on primary respiratory epithelial cells, Saiman and
colleagues showed that superﬁcial amounts of A-GM1 were
present in 12% of primary CF airway cells, compared to 2.9% of
cells in normal control subjects (Saiman and Prince, 1993). More
recently, Adamo and colleagues showed that P. aeruginosa ﬂagella
activate airway epithelial cells through binding with A-GM1 and
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antibodies in recognizing SLs remains one of the most debated
issues in the scientiﬁc community working on SLs. One of the main
criticisms, already conﬁrmed for several SL-binding proteins such
as cholera toxin, is related to their capability to recognize single
molecules or a cluster of different species of lipids (Krivan et al.,
1988a,b; de Bentzmann et al., 1996; Adamo et al., 2004; McNamara
et al., 2006).
Also under debate is the role of Cer in CF inﬂammation and
infection. Guilbault et al. (Guilbault et al., 2008, 2009) demon-
strated, using mass spectroscopy that the plasma of CF patients
displays signiﬁcantly low levels of several Cer species, in particular,
C14:0, C20:0, C22:0, C22:1 and C24:0 Cer and dihidroxy Cer (DHC
16:0). Using TLC-ELISA, they found an overall reduction (about 4
times less) of Cer content in lung, plasma, ileum and pancreas in
C57BL/6-CFTR/ mice compared to WT mice. Interestingly,
heterozygous mice, which possess one normal and one ablated
allele of CFTR gene, had a 1.9-fold reduction of Cer in the lungs, a 2-
fold reduction in the plasma, a 3.4-fold reduction in the ileum, and
a 1.9-fold reduction in the pancreas compared to WT mice.
Using immortalized human respiratory tracheal epithelial cells,
(Vilela et al., 2006) tried to elucidate the possible molecular
mechanism responsible for Cer reduction in CF. They found that
CFTR-deﬁcient tracheal epithelial cells are characterized by high
glutathione levels that decrease the intracellular content of Cer
through the inhibition of neutral sphingomyelinase. Cer deﬁciency
occurring in CF seems to be responsible for the increased activation
of the pro-inﬂammatory transcriptional nuclear factor (NF)-kB
that in turn is responsible for the abnormally high inﬂammatory
response in CF respiratory epithelial cells. In fact, increasing Cer
levels by treating CF/ mice or CFTR-deﬁcient tracheal epithelial
cells with fenretinide, results in an improved ability to control P.
aeruginosa infections (Lavrentiadou et al., 2001; Vilela et al., 2006;
Guilbault et al., 2008). However, the mechanism underlying this
treatment is unknown. Further studies on the involvement of Cer
in the control of inﬂammatory response is needed to detail, in
particular, the mechanism involving the glutathione-dependent
neutral sphingomyelinase inhibition as well as the subcellular
localization of the signalling Cer.
Different results were reported by Teichgraber and colleagues
showing an accumulation of Cer in CF lung disease (Teichgraber
et al., 2008). In fact, the authors showed an age-dependent
accumulation of Cer in the respiratory tract of uninfected mutant
mice lacking functional CFTR. In addition, they found Cer
accumulation in ciliated respiratory cells and in the submucosa.
From a mechanistic point of view, they suggested that the loss of
CFTR induces an alkalinization of intracellular vesicles that
strongly reductes or reverses acid ceramidase activity without
substantial modiﬁcations to the activity of the acid sphingomye-
linase (ASMase) (Teichgraber et al., 2008). The imbalance of
ASMase and acid ceramidase activity results in a net accumulation
of Cer. The accumulation of Cer is also responsible for age-
dependent pulmonary inﬂammation, the death of respiratory
epithelial cells, and the high susceptibility to severe P. aeruginosa
infections. Interestingly, the genetic or pharmacological inhibition
of the acid sphingomyelinase causes a reduction of Cer levels,
resulting in an amelioration of the inﬂammatory response to P.
aeruginosa infections (Becker et al., 2010). These controversial
ﬁndings seem to be due to the intrinsic differences among the
different mouse models used, as well as the special diet required
for CFTR knockout mice. Mice completely lacking CFTR need a
PeptamenR-based diet in order to prevent intestinal obstruction.
PeptamenR is normally used for the dietary management of
patients with compromised or impaired gastro-intestinal function.
This includes patients suffering from conditions such as malab-
sorption, diarrhea, intolerance to standard enteral formulas,delayed gastric emptying, short-bowel syndrome, inﬂammatory
bowel disease and pancreatic insufﬁciency. Teichgraber and
colleagues demonstrate that this particular diet induces an
accumulation of cholesterol in the lung that is responsible for
the 60% inhibition of ASMase, which in turn causes a reduction of
Cer levels in the lung (Teichgraber et al., 2008). Interestingly, the
effect of a PeptamenR diet on Cer and ASMase in the lung was
abrogated by treatment with simvastatin, a known blocker of
cholesterol biosynthesis (Mol et al., 1986; Teichgraber et al., 2008).
Despite these contradictory results, probably due to different
analytical approaches used, Brodlie and colleagues, described an
increase in Cer content in the lower airway epithelium of CF
patients with advanced lung disease for the ﬁrst time. The results
were obtained using different experimental approaches, ranging
from immunochemistry to high-performance liquid chromatogra-
phy-mass spectrometry. In particular, they found signiﬁcantly
elevated levels of Cer C16:0, C18:0 and C20:0. Additionally, Cer was
signiﬁcantly increased in lungs colonized by P. aeruginosa (Brodlie
et al., 2010).
The role of Cer in determining the host defence against P.
aeruginosa represents one of the hot topics in CF research. In
Grassmé et al. (2001) is described how P. aeruginosa infection
triggers the activation of ASMase through its translocation to the
plasma membrane in normal epithelial cells. At this site it catalyzes
SM hydrolysis, resulting in the production of Cer that, together
with CD95 clusterization, promotes P. aeruginosa internalization,
induces apoptosis, and regulates the cytokine response in infected
cells.
Cer seems to be also involved in the susceptibility of CF patients
to microbial colonization, in particular to P. aeruginosa, which
might be explained, at least in part, by the alteration of its levels in
lung macrophages. Zhang and colleagues demonstrated that in
CFTR-deﬁcient macrophages, alkalinization of intracellular acid
vesicles is correlated with the lack of response of these cells to
infections caused by various strains of P. aeruginosa (Zhang et al.,
2010). In contrast to the wild type, CFTR-deﬁcient macrophages are
defective in the acute activation of ASMase, which produces Cer
that serves to cluster gp91phox (an important membrane-bound
subunit of the NADPH oxidase) and to release reactive oxygen
species. The absence of these responses to bacterial infection may
result in a persistence of P. aeruginosa in the lung.
These ﬁndings open the possibility of targeting Cer metabolism
as new therapeutic strategies for CF lung disease (Teichgraber et al.,
2008; Guilbault et al., 2009; Yu et al., 2009; Bodas et al., 2010;
Brodlie et al., 2010; Dechecchi et al., 2011; Nahrlich et al., 2013).
In P.aeruginosa infection and the basal pro-inﬂammatory state
typical of CF patients, new evidence supports the role of Cer, which
is catabolized from complex GSLs directly at the cell surface by
different plasma membrane-associated glycohydrolases. In partic-
ular, a pivotal role is exerted by GBA2, a transmembrane beta-
glucocerebrosidase involved in the production of Cer by the
hydrolysis of GlcCer mainly at PM level. Treatment of CF epithelial
bronchial cells with miglustat, an inhibitor of the cellular beta-
glucocerebrosidases, has been found to reduce the immune
response to P. aeruginosa infection (Loberto et al., 2014). In fact,
treating CF epithelial bronchial cells with miglustat down-
regulates the expression of the main genes up-regulated by P.
aeruginosa in CF, such as chemokines (IL-8, growth-regulated Gro-
a/b/g proteins, and granulocyte chemotactic peptide-2 [GCP-2]),
proinﬂammatory cytokines (IL-1 a/b, IL-6, and TNF-a), and the
intercellular adhesion molecule–1, nuclear factor kB1, TLR2, and
the human defensin B4 genes. Moreover, it has been demonstrated
that GBA2 inhibition by miglustat results in a reduction of Cer
formation at the PM of CF human bronchial cells infected by P.
aeruginosa. Consequently, a possible relationship between GBA2
and inﬂammatory response has been proposed. Similar effects of
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also observed in CF human bronchial epithelial cells exposed to P.
aeruginosa by lowering GBA2 expression with siRNA oligonucleo-
tides (Loberto et al., 2014).
These ﬁndings parallel the attenuation of systemic inﬂamma-
tion with the deletion of the GBA2 gene in a mouse model of
Gaucher disease 1. In particular, a very impressive reduction of IL-2,
IL-6, GM-CSF and the murine IL-8 homologue, keratinocyte-
derived chemokine KC was found (Mistry et al., 2014). Therefore,
GBA2 may determine the susceptibility to inﬂammatory stimuli
due to its ability to modify the lipid organization at the plasma
membrane level.
The contribution of PM glycohydrolases in the production of Cer
in response to bacterial infections, and the involvement of these
enzymes in determining the high concentrations of Cer found in
the airway of the CF patients, could be higher than expected. This
possibility is related to the fact that, besides the up-regulation of
these enzymes in CF, the possibility of an acidiﬁcation of the
extracellular milieu of the CF-related organs, including the lungs
(Machen, 2006), could further up-regulate glycohydrolases. In fact,
most of these enzymes are most effective in low pH values;
therefore, an acidic extracellular environment could in turn induce
their activation and increase the in-situ hydrolysis of complex GSLs
with production of Cer. The main open question is to understand if
Cer works directly as a signaling molecule or if the increased
activity of PM glycohydrolases is responsible for a general
reorganization of the cell plasma membrane with the formation
of a speciﬁc signaling platform. Cer is a very hydrophobic
compound and, as a pure component, it is insoluble in aqueous
solution. Within a membrane, it can be considered an amphiphilic
molecule due to the primary hydroxyl group and the amide planar
linkage located at the water–lipid interface. On the other hand, the
speciﬁc interaction between SLs and protein is widely described.
We argue that for these reasons, it is not surprising that when Cer is
produced from complex SLs, the membrane undergoes a deep
reorganization that in turn is responsible for the modiﬁcations of
the cellular signaling.
Another actor in CF is represented by the sphingoid long chain
base, sphingosine, in determining susceptibility to lung infection
caused by P. aeruginosa. Tracheal and bronchial sphingosine levels
were signiﬁcantly reduced in tissues from CF patients and from CF
mouse models due to a reduction in the activity of acid ceramidase,
which generates sphingosine from Cer, thus leading to Cer
accumulation. Therefore, in CF cells, the distribution of sphingo-
sine and Cer is inversely related. Furthermore, the inhalation with
sphingosine, the sphingosine analog FTY720, or with acid
ceramidase induces a rescued in susceptible mice from P.
aeruginosa infection, suggesting that sphingosine plays an impor-
tant role in antibacterial defense in healthy lungs (Pewzner-Jung
et al., 2014). In summary, the balance between Cer and sphingosine
concentrations seems to determine the susceptibility to P.
aeruginosa infection, although they are not the only molecules
controlling infections.
5. Relationship between CFTR and sphingolipids
Since the discovery of the CFTR gene, there has been worldwide
interest in pharmacologic approaches to identify a single agent
capable of restoring mutant CFTR to therapeutically relevant levels
(Ramsey et al., 2011; Boyle et al., 2014; Solomon et al., 2015).
Most of studies on CFTR interactome have focused on protein-
protein interactions without considering that CFTR is a transmem-
brane protein associated with lipid rafts (Kowalski and Pier, 2004;
Abu-Arish et al., 2015). Given CFTR localization within plasma
membrane regions enriched in SLs, we speculate the existence of
interactions between SLs and proteins that participate in thestabilization or to the function of CFTR. Relevantly, data emerging
from literature indicate that CFTR is both regulated by SLs and/or is
involved in the regulation of SL metabolism. For this latter point, a
regulatory relationship between expression of CFTR and SL
synthesis has been reported (Hamai et al., 2009). In particular,
expression of defective CFTR, i.e., the F508del mutation of CFTR or
decreased CFTR expression, increases SL synthesis, resulting in a
signiﬁcantly increased mass of SM, sphingosine, and sphinganine.
Moreover, the mass of four saturated long-chain Cer species, such
as C16-di-hydroCer and C22- C24- C26-Cer, proportionally
increased up two fold for C22–C24 and 1.5 fold for C16-di-
hydroCer and C26. On the other hand, Cer species containing C18:0
and C18:1 fatty acids decreased. These data suggest that failure to
express CFTR has distinct effects on Cer species composition,
although exact mechanisms are currently unknown. The signiﬁ-
cance of altered Cer composition, speciﬁcally of increased
saturated long-chain Cer, may be a cellular response to the lack
of CFTR, which consequently leads to plasma membrane destabi-
lization. The expression of defective CFTR, previously reported to
coincide with characteristics of a destabilized membrane, may
trigger the synthesis of a class of lipids that promotes membrane
stabilization (Thelin et al., 2007). If membrane stability is indeed
affected by the expression of defective CFTR, then an increase in SL
synthesis, including that of SM, could be a compensatory
mechanism directed to increase membrane stability or em-
bedment of CFTR into the SL and cholesterol-rich membrane
regions.
For instance, Itokazu and colleagues describe a direct correla-
tion between ganglioside GM1 PM levels and CFTR expression
(Itokazu et al., 2014). In particular, they found that CFTR-silenced
human airway cells had a 60% decrease in GM1, reduced b1-
integrin activation, decreased phosphorylated tyrosine 576 of focal
adhesion kinase (pFAK), and phosphorylation of Crk-associated
substrate (pCAS), which resulted in a reduction of cell motility. The
addition of GM1 (but not GM3) ganglioside to CFTR-silenced cells
restored activated b1-integrin, pFAK, and pCAS to near control
levels and partially restored (40%) cell migration. The decreased
GM1 content in CFTR-silenced cells is consistent with studies
demonstrating lower GM1 in CFTR-deﬁcient cells compared to
normal cells. They also demonstrated that reduced GM1 in CFTR-
silenced cells was a result of loss of CFTR function, since the
expression of GFP-CFTR in CFTR-silenced cells signiﬁcantly
increased GM1 levels, whereas the pharmacologic inhibition of
CFTR in control cells decreased GM1. However, the mechanisms
underlying this alteration in gangliosides have never been
identiﬁed even if preliminary data seem to suggest an involvement
of the lysosomal compartment. These results suggest that
decreased GM1 in CFTR-silenced cells depresses b1-integrin
signaling, which contributes to the delayed wound repair observed
in these cells. These ﬁndings have implications for CF pathology,
where altered SL levels in airway epithelial cells might result in a
diminished capacity for wound repair after injury.
For the regulation of the CFTR function by the PM micro-
environment, it has been reported that the clusterization of CFTR in
membrane areas rich in Cer causes an inhibition in its chloride
channel function (Ramu et al., 2007). In particular, the authors
describe that inhibition of the CFTR current is the result of the
enzymatic hydrolysis of SM, leading to the formation of Cer, which
makes it more difﬁcult to activate CFTR by phosphorylation of the R
domain. This would then imply that SM, complexed to CFTR,
promotes the channel gating in a way that cannot be duplicated by
Cer or Cer-1-phosphate. On the other hand, recent investigation
demonstrates that S1P inhibits CFTR via adenosine monophos-
phate-activated kinase (AMPK) (Malik et al., 2015).
Many respiratory pathogens have SMase activity and P.
aeruginosa, one of the major offenders, which permanently
M. Aureli et al. / Chemistry and Physics of Lipids 200 (2016) 94–103 101colonizes the airways of virtually all of CF patients and secretes a
phospholipase (termed PLC-H) working as a virulence factor that
can hydrolyze SM in situ, leading to the formation of Cer
(Stonehouse et al., 2002). In this frame, P. aeruginosa infection
reducing CFTR chloride channel activity produces a negative
impact on mucociliary clearance and consequently on the ability of
airways to clear bacteria, resulting in an aggravation of the CF
phenotype. The molecular mechanism linking the CFTR loss of
function to Cer clusterization is still unknown.
Many studies report that P. aeruginosa reduces apical mem-
brane expression and the chloride secretion of both wild-type (wt)
and rescued F508del CFTR in respiratory epithelia by inhibiting
apical endocytic recycling (Swiatecka-Urban et al., 2006; MacEach-
ran et al., 2007; Bomberger et al., 2011). Recently, it has been
observed that P. aeruginosa infection initially results in the post-
translational modiﬁcation of Na+/H+ exchange regulatory factor1
(NHERF1), causing an almost complete removal of CFTR from the
apical membrane both in vitro and in vivo (Rubino et al., 2014). An
important function of NHERF1 is the binding of its carboxy-
terminal domain to ezrin. This scaffolding protein is a member of
the ezrin/radixin/moesin (ERM) protein family comprising critical
regulators of cytoskeletal-plasma membrane interactions (Pearson
et al., 1977). Indeed, the NHERF1-dependent increase of apical
membrane wt and F508del CFTR occurs via the re-organization of
the actin cytoskeleton by inducing the formation of the multi-
protein complex NHERF1-RhoA-ROCK-ezrin-actin (Favia et al.,
2010; Monterisi et al., 2012).
Furthermore, ezrin is a PKA-anchoring protein and, in its
opened form, may recruit the regulatory subunit of PKA to the
proximity of CFTR, leading to its activation (Sun, 2000). Recently, it
has been demonstrated that ERM proteins are strongly regulated
by SLs. Indeed, the hydrolysis of plasma membrane SM, induced by
bacterial sphingomyelinases, produces Cer that promotes ERM
dephosphorylation through the activation of protein phosphatases
(Hannun and Obeid, 2008; Canals et al., 2010). On the other hand,
due to the physico-chemical properties of Cer, its increase on the
plasma membrane could also sequester the CFTR in a rigid region
that does not allow phosphorylation of the R domain. In fact, the
rapid increase of Cer exerted by the in-situ hydrolysis of SM is
followed by its spontaneous segregation. This process requires
total rearrangement of the membrane, obtained by excluding some
components and sorting others. In this context, it is not difﬁcult to
imagine that the original lipid-protein interactions undergo
modiﬁcations and that the forces exerted by the lipid environment
on the protein conformation could result in changes of the
biological properties of proteins and of protein-protein interac-
tions.
6. Conclusions and perspectives
Despite the availability of a wide spectrum of therapeutic
options, the onset of lung disease characteristic of Cystic Fibrosis
represents the highest challenge to overcome in order to reduce CF
mortality. Although several ﬁndings clearly indicate altered SL
metabolism in CF pulmonary disease, unfortunately, the direct
involvement of SLs in the pathogenesis of CF lung disease is still
unclear. In particular, it is not clear what the relationships between
CFTR and SL metabolism and its dependence on membrane
organization are. This opens the discussion, poorly addressed by
the scientiﬁc community, on the importance of the lipid micro-
environment in the regulation of the biological activity of plasma
membrane-resident proteins, such as CFTR. For example, changes
in SL composition associated with CF lung disease can directly
determine a different membrane organization, which, in turn,
could decrease CFTR stability and function. We think that it is
fundamental to address this issue not only to deﬁne the molecularmechanisms involved in CF disease, but also in other pathologies
caused by alteration in the activity of PM-associated proteins.
Future progress in understanding the critical roles of SLs in these
processes could open new perspectives for the development of
alternative SL-based therapeutic strategies to reduce the inﬂam-
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